Thomas Gasser
Parkinson Genetics
Prof. Dr. Thomas Gasser
Head of clinical research Tübingen,
Group Leader
Hoppe-Seyler-Str. 3
72076  Tübingen
 +49 7071 29-86529


The group of Prof. Gasser focuses on the study of Parkinson's syndrome, which is the second most common neurodegenerative disease after Alzheimer's disease with steadily increasing prevalence. The group is looking at the analysis of genetic factors that play a role in Parkinson's disease and how this knowledge can be used to determine which proteins positively influence the onset and progression of Parkinson's disease.

The genetic variants known today can only explain a small part of the overall risk of the disease. In order to obtain a more complete picture of the entire genetic risk profile and to derive new approaches for diagnosis, prevention or therapy, as complete genetic data sets as possible must be examined by many thousands of patients. In large international consortia, such as the International Parkinson's Disease Genomics Consortium (IPDGC), the research group conducts such studies in collaboration with many colleagues from around the world. Patients with mutations in certain genes, however, are already being tested in new progression-modifying therapies based on genetically caused metabolic disorders.

Key Publications

Kathrin Brockmann, Karin Srulijes, Sylvia Pflederer, Ann-Kathrin Hauser, Claudia Schulte, Walter Maetzler, Thomas Gasser, Daniela Berg. GBA-associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study. Movement Disorders. 2015 Feb 28; 30:407-411. doi: 10.1002/mds.26071
Michael A. Nalls, Vincent Plagnol, Dena G. Hernandez, Manu Sharma, Una-Marie Sheerin, Mohamad Saad, Simón-Sánchez, Claudia Schulte, Suzanne Lesage, Sigurlaug Sveinbjörnsdóttir, Kári Stefánsson, Maria Martinez, John Hardy, Peter Heutink, Alexis Brice, Thomas Gasser, Andrew B. Singleton, Nicholas W. Wood. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: A meta-analysis of genome-wide association studies. The Lancet. 2010 Dec 31; 377:641-649. doi: 10.1016/S0140-6736(10)62345-8
Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, …, Gasser T. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009 Jan 01; 41:1308-12. doi: 10.1038/ng.487
Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Müller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004 Nov 18; 44:601-7. doi: 10.1016/j.neuron.2004.11.005
Zimprich A, Grabowski M, Asmus F, Naumann M, Berg D, Bertram M, Scheidtmann K, Kern P, Winkelmann J, Müller-Myhsok B, Riedel L, Bauer M, Müller T, Castro M, Meitinger T, Strom TM, Gasser T. Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet. 2001 Sep 01; 29:66-9. doi: 10.1038/ng709


Thursdays 1:30-4:30 pm

Patients +49 800-7799001

(free of charge)

Professionals +49 180-779900

(9 Cent/Min. German landline, mobile and out of Germany possibly more expensive)

Welcome to our website, here you can inform yourself basically cookie-free.

We would be pleased if you would allow a cookie to be set for analysis purposes in order to optimise our provided information. All data are pseudonymous and are only used by the DZNE. We deliberately avoid third-party cookies. You can deselect this setting at any time here.

Your browser allows the setting of cookies: